Gyre Therapeutics (GYRE) Capital Expenditures Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
- |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
46.88% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Gyre Therapeutics |
554.75 Mn |
540.62 Mn |
8.38 Mn |
-53.25% |
| Date | Value |
|---|
| Mar 31, 2026 |
-53.25% |
| Sep 30, 2024 |
12.10% |
| Sep 30, 2023 |
116.32% |
| Jun 30, 2023 |
436.95% |
| Mar 31, 2023 |
367.95% |
| Mar 31, 2020 |
78.28% |
| Dec 31, 2019 |
-26.16% |
| Sep 30, 2019 |
-64.31% |
| Jun 30, 2019 |
-40.70% |
| Mar 31, 2019 |
-44.76% |
| Dec 31, 2018 |
21.32% |
| Dec 31, 2016 |
63.77% |
| Jun 30, 2016 |
120.23% |
| Mar 31, 2016 |
8.33% |
| Dec 31, 2015 |
-20.49% |
| Dec 31, 2013 |
-26.65% |
